Initiation of a Phase II clinical trial with anti-KIR monoclonal antibody IPH 2101 in smoldering myeloma patients
Innate Pharma announced that it has started patient inclusion in a new multicenter Phase II clinical trial with IPH 2101, an anti-KIR monoclonal antibody potentiating the anti-tumor activity of NK cells. In this trial, IPH 2101 is tested as a single agent in patients with smoldering myeloma, an early state of the blood malignancy multiple myeloma. The trial is conducted in the United States at multiple major hospitals (IPH2101-203 or “KIRMONO” trial).
“This is an important study for IPH 2101 as it will test the drug candidate in patients with early disease and a limited tumor burden - a favorable setting for immunotherapy. Furthermore, this is the first trial to be initiated and sponsored by Innate Pharma in the USA. We are delighted to have the support of leading clinical groups such as the Dana Farber Cancer Institute (“DFCI”) in Boston”, said Marcel Rozencweig, MD, Innate Pharma's Executive Vice President and Chief Medical Officer.
Nikhil C. Munshi, MD, a DFCI investigator and Associate Professor of Medicine at Harvard Medical School, added: “We are very interested in testing IPH 2101 in this patient population: the anti-tumor effect of NK cells seems to play an important role in the control of plasma cell proliferation and might be easily enhanced by IPH 2101. Furthermore, IPH 2101 has been very well tolerated so far. This is a key feature for patients with asymptomatic disease for whom there is no established standard of care”.
Other news from the department research and development
